Skip to content
HowShorted

EAGLE PHARMACEUTICALS, INC. short interest in 2019

In 2019, EAGLE PHARMACEUTICALS, INC.'s disclosed short interest ran from 18.97% of shares outstanding on 15 Jan 2019 to 12.38% on 31 Dec 2019, a change of -6.59 percentage points. The year's high was 18.97% on 15 Jan 2019 and its low 10.74% on 31 Oct 2019, averaging 14.41% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.78 days on 31 Jul 2019. Full history: EAGLE PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for EAGLE PHARMACEUTICALS, INC. in 2019

2019 in figures

Start of year
18.97% (15 Jan 2019)
End of year
12.38% (31 Dec 2019)
Change
-6.59 pp
High
18.97% (15 Jan 2019)
Low
10.74% (31 Oct 2019)
Average
14.41%
Highest days to cover
17.78 (31 Jul 2019)
SEC filings marked
8

Every report in 2019

EAGLE PHARMACEUTICALS, INC. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201918.97%15.85
31 Jan 201918.29%13.37
15 Feb 201917.85%16.91
28 Feb 201915.74%7.0310-K filed, results (8-K)
15 Mar 201915.21%9.94
29 Mar 201913.58%14.46
15 Apr 201913.12%11.46
30 Apr 201913.79%9.87
15 May 201914.42%7.7410-Q filed, results (8-K)
31 May 201915.92%11.81
14 Jun 201916.23%15.49
28 Jun 201915.66%13.34
15 Jul 201915.55%16.87
31 Jul 201915.38%17.78
15 Aug 201915.26%14.2110-Q filed, results (8-K)
30 Aug 201914.66%15.35
13 Sep 201914.04%10.59
30 Sep 201912.65%9.64
15 Oct 201911.43%10.61
31 Oct 201910.74%13.07
15 Nov 201911.48%9.8510-Q filed, results (8-K)
29 Nov 201911.98%12.95
13 Dec 201911.45%10.76
31 Dec 201912.38%15.06

See also: EAGLE PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.